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bjectives We sought to identify correlates of 30-day adverse events among patients undergoing
ercutaneous coronary intervention (PCI) of saphenous vein grafts (SVG).
ackground Although the use of distal embolic protection devices during SVG intervention reduces
ajor adverse cardiac events (MACE), many patients still experience MACE despite distal embolic
rotection, and the major predictors of MACE among these patients are not well-characterized.
ethods Correlates of 30-day MACE and peri-procedural creatine kinase-myocardial band (CK-MB)
levation were assessed among 631 patients undergoing SVG intervention with distal embolic pro-
ection enrolled in the PRIDE (PRotection during saphenous vein graft Intervention to prevent Distal
mbolization) study, a randomized comparison of the TriActiv System (Kensey-Nash Corp., Exton,
ennsylvania) with an active control group (Guardwire [Medtronic, Santa Clara, California] or Filter-
ire [Boston Scientiﬁc, Minneapolis, Minnesota]).
esults Baseline covariates associated with MACE were longer lesion length, greater angiographi-
ally assessed estimated plaque volume, and higher SVG degeneration score. Graft age and angina
lass were not associated with adverse events. Angiographic lesion length was signiﬁcantly corre-
ated with more complex angiographic metrics such as estimated plaque volume and the SVG de-
eneration score. In multivariable analyses, angiographic lesion length was the strongest indepen-
ent correlate of MACE (odds ratio [OR] 2.81 [95% conﬁdence interval (CI) 1.82 to 4.34]/log-increase
n lesion length, p  0.001) with a graded increase in MACE observed with increasing lesion
engths. Similarly, the strongest independent correlate of CK-MB elevation was lesion length (OR
.54 [95% CI 1.59 to 4.04]/log-increase in lesion length, p  0.001). The associations between lesion
ength and both MACE and CK-MB elevation were consistent among the studied embolic protection
evices (TriActiv, Guardwire, or Filterwire).
onclusions Angiographic lesion length was the strongest correlate of short-term adverse events
mong patients undergoing SVG intervention with distal embolic protection, with incremental
ffects noted at even relatively short lesion lengths. (J Am Coll Cardiol Intv 2008;1:186–91)
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187he percutaneous treatment of diseased saphenous vein
rafts (SVGs) represents one of the major current challenges
f current percutaneous coronary intervention (PCI). De-
pite major advances in PCI technique and technology,
atients with diseased SVGs still represent one of the
ighest-risk subgroups of patients undergoing PCI. Percu-
aneous treatment of SVGs has been associated with a
reater incidence of slow flow and higher rates of peri-
rocedural myocardial infarction, largely owing to distal
mbolization of the abundant and friable atherosclerotic
ebris in diseased SVGs.
Although the embolic protection with either balloon
cclusion devices or filter-based devices during SVG PCI
educes major adverse cardiac events (MACE), many pa-
ients undergoing SVG PCI still experience adverse events
1–5). Prior reports of the major correlates of MACE
mong patients undergoing contemporary SVG PCI have
ncluded a mixed cohort of patients treated both with and
ithout embolic protection (3,6–10) or have been limited
y small sample size (11). Therefore we sought to identify
orrelates of adverse events among a cohort of SVG PCI
atients uniformly treated with distal embolic protection.
ethods
ata were compiled from 631 subjects undergoing SVG
CI in the PRIDE (PRotection during saphenous vein graft
ntervention to prevent Distal Embolization) Study. The
RIDE was a prospective, randomized clinical trial of the
riActiv System (Kensey-Nash Corp., Exton, Pennsylva-
ia) device with an active control (either Guardwire
Medtronic, Santa Clara, California] or Filterwire [Boston
cientific, Minneapolis, Minnesota]) in patients undergoing
CI of an SVG (12). Criteria for inclusion were age 21
ears, angina or objective evidence of ischemia, lesion in an
VG (3.0 and 5.0 mm in diameter), Thrombolysis In
yocardial Infarction (TIMI) flow grade 0, and ability to
rovide informed consent. Patients were excluded if any of
he following were present: pregnancy; lesion in a native
rtery or internal mammary graft; distal shoulder of the
esion within 2.0 cm of the distal anastamosis; left ventric-
lar ejection fraction 25%; sequential grafts, unless the
esion was 2 cm proximal to the branch point; myocardial
nfarction (creatine kinase [CK] and creatine kinase-
yocardial band [CK-MB] more than twice the upper limit
f normal within 24 h); allergy to aspirin, clopidogrel, or
iclopidine; treatment of 2 SVGs; and comorbidities
imiting life-expectancy to 6 months. The PRIDE study
as approved by the institutional review board at each site;
ll patients provided written informed consent to partici-
ate.
Randomization was stratified by intention to administer a
lycoprotein IIb/IIIa receptor antagonist before interven-
ion. Patients received aspirin before the procedure and Tither heparin or bivalirudin during the procedure. After the
rocedure, aspirin and either clopidogrel or ticlopidine were
dministered for a minimum of 1 month. Cardiac enzymes
ere routinely assessed every 8 h for 24 h. Patients were
ssessed clinically at 30 days.
For this analysis, subjects included were those in Cohort
of the trial (randomized comparison of TriActiv System
s. Guardwire or Filterwire). Subjects in Cohort 1 (random-
zed comparison of TriActiv System vs. no embolic protec-
ion) were not included. All angiographic data were assessed
ffline by an independent core laboratory with quantitative
oronary angiography methodology that has been described
reviously (3). The primary end point for this analysis was
he occurrence of 30-day MACE (cardiac death, myocardial
nfarction [any post-procedure CK-MB level 3  the
pper limit of normal], or target lesion revascularization) on
per-patient level. The MACE was adjudicated by an
ndependent clinical events committee blinded to device
ssignment. Peri-procedural myocardial infarction (as de-
ned earlier) was a secondary end point.
tatistical analysis. Continuous
ariables are reported as means
ith SDs and categorical vari-
bles as rates or proportions.
he t test was used to compare
ontinuous variables, and the
hi-square test was used for
omparisons of categorical vari-
bles. Variables that were not
ormally distributed were ap-
ropriately transformed (e.g., le-
ion length was left-skewed and
as therefore log-transformed
ith natural logarithms). Logis-
ic regression multivariable analyses were performed, includ-
ng candidate covariates associated with the outcome of
nterest (MACE, CK elevation) with p  0.05 in univariate
nalyses. Stepwise selection was used to develop final
odels. All analyses were performed by an independent
tudy statistician (ERH) with SAS Version 8.2 (SAS
nstitute, Cary, North Carolina).
esults
he mean patient age was 69 years, with 82% male and 41%
iabetic subjects (Table 1). The mean graft age was 12 years,
nd treated grafts had a mean reference diameter of 3.3 mm,
mean percent diameter stenosis of 65%, and a mean lesion
ength of 14 mm. Angiographic thrombus was present in
8% of lesions, and 11% of grafts had abnormal TIMI flow
rade. Coronary stents were successfully delivered in 585 of
31 (92.7%) patients. After PCI, the mean residual diam-
ter stenosis was 14%, with 11% of grafts having abnormal
Abbreviations
and Acronyms
CI  confidence interval
CK-MB  creatine kinase-
myocardial band
MACE  major adverse
cardiac events
OR  odds ratio
PCI  percutaneous
coronary intervention
SVG  saphenous vein graftIMI flow grade. Device success was observed in 99% of
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188ases, with no significant differences between treatment
roups in the overall cohort (p  0.68 for comparison with
riActiv System vs. active control).
Adjudicated MACE was observed in 67 (10.6%) patients,
ith CK-MB elevation occurring in 56 of 549 (10.2%)
atients. The univariate correlates of MACE and CK-MB
levation are shown in Table 2. The only baseline covariates
ssociated with MACE were history of cigarette smoking,
esion length, estimated plaque volume, and SVG degener-
tion score. The baseline covariates associated with peri-
rocedural CK-MB elevation were very similar and in-
luded female gender, history of cigarette smoking, lesion
ength, estimated plaque volume, and SVG degeneration
core. Of note, neither graft age nor angina class at
resentation was associated with adverse peri-procedural
Table 1. Baseline Characteristics
Parameter MACE
Age, yrs (mean  SD) 67.8  12.7
Male gender 51 (76.1%)
CCS class I 8 (12.1%)
CCS class II 12 (18.2%)
CCS class III 26 (39.4%)
CCS class IV 20 (30.3%)
Prior MI 49 (75.4%)
Diabetes mellitus 27 (40.3%)
Dyslipidemia requiring medication 58 (86.6%)
Hypertension 61 (91.0%)
Cigarette smoking 18 (27.3%)
Family history of premature CAD 19 (36.5%)
Positive functional test 22 (32.8%)
GP IIb/IIIa planned 37 (55.2%)
Before PCI
Mean graft age (yrs) 11.5  5.9
Graft to LAD 10 (15.2%)
Graft to LCX 26 (39.4%)
Graft to RCA 31 (47.0%)
Lesion length 20.1  15.0
Reference vessel diameter 3.3  0.6
Minimum lumen diameter 1.2  0.6
Baseline % stenosis 64.8  15.8
% with thrombus 44 (66.7%)
Baseline TIMI ﬂow grade 2.9  0.4
SVG degeneration (4-point scale) 2.1  1.1
Plaque volume 479  383
After PCI
Reference vessel diameter 3.3  0.5
Minimum lumen diameter 2.8  0.7
% stenosis 17.0  15.9
% with thrombus 13 (19.7%)
TIMI ﬂow grade 2.8  0.6
CAD coronary artery disease; CCS Canadian Cardiovascular Society; GP IIb/IIIa glycoprotein I
MImyocardial infarction; PCI percutaneous coronary intervention; RCA right coronary artery;utcomes (Table 1). iA strong and graded association between increasing
esion length and the incidence of MACE and CK-MB
levation was observed (Fig. 1). Lesion length was signifi-
antly correlated with estimated angiographically estimated
laque volume as well as the SVG degeneration score (r 
.83 for plaque volume; r  0.49 for SVG degeneration
core). Because lesion length, SVG degeneration score, and
ngiographic plaque volume were highly correlated, only the
ovariate with the strongest association with the study end
oints (lesion length) was included in final multivariable
odels to avoid multicollinearity.
In multivariable analyses, lesion length remained the
trongest independent correlate of MACE (odds ratio [OR]
.81 [95% confidence interval (CI) 1.82 to 4.34]/log-increase
n lesion length, p  0.001). Similarly, the most significant
No MACE p Value
68.6  9.8 0.52
465 (82.5%) 0.20
75 (13.4%) 0.51
146 (26.1%) —
159 (28.4%) —
179 (32.0%) —
352 (65.1%) 0.10
235 (41.7%) 0.83
486 (86.2%) 0.93
472 (84.1%) 0.14
90 (16.4%) 0.028
180 (37.4%) 0.90
208 (37.3%) 0.48
297 (52.7%) 0.69
12.0  5.9 0.51
146 (26.0%) 0.054
235 (41.8%) 0.71
203 (36.1%) 0.08
13.0  8.7 0.001
3.2  0.6 0.27
1.1  0.6 0.49
65.5  14.8 0.75
323 (57.7%) 0.16
2.8  0.5 0.66
1.7  0.9 0.001
313  266 0.001
3.3  0.6 0.48
2.8  0.6 0.59
14.0  9.4 0.023
54 (9.6%) 0.012
3.0  0.2 0.001
ceptor antagonist; LAD left anterior descending (artery); MACEmajor adverse cardiac events;
right circumflex (artery); SVG saphenous vein graft; TIMI Thrombolysis InMyocardial Infarction.Ib/IIIa rendependent correlate of peri-procedural CK-MB elevation
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1893 the upper limit of normal was lesion length (OR 2.54
95% CI 1.59 to 4.04]/log-increase in lesion length, p 
.001). The association between lesion length and either
ACE or CK-MB elevation was significant and consistent
mong the 3 different types of distal embolic protection
evice used in the trial and regardless of whether the use of
lycoprotein IIb/IIIa inhibitors was planned (all p values for
nteraction not significant).
iscussion
n this analysis of 631 patients undergoing SVG PCI using
istal embolic protection, angiographic lesion length was
he only independent correlate of adverse clinical outcomes.
espite the use of embolic protection, the association
etween lesion length and adverse outcomes was graded and
ontinuous, with 20% rates of peri-procedural MACE
bserved for lesions 20 mm in length.
The use of embolic protection devices as an adjunct to
VG PCI has been demonstrated to reduce the occurrence
f peri-procedural events by approximately 40% (1). Al-
Table 2. Univariate Predictors of CK-MB Elevation and Adjudicated MACE
Parameter
CK-MB >3 
OR (95% CI)
Male gender 0.53 (0.28–0.99)
Age (/yrs) 1.00 (0.98–1.03)
CCS class 1.02 (0.78–1.34)
Prior MI 1.35 (0.72–2.53)
PVD 0.82 (0.42–1.61)
Prior CVA/TIA 0.74 (0.31–1.80)
Diabetes mellitus 0.72 (0.40–1.28)
Dyslipidemia requiring medication 0.81 (0.38–1.72)
Hypertension 2.34 (0.82–6.67)
Cigarette smoking 2.09 (1.12–3.93)
Family history of premature CAD 1.17 (0.61–2.22)
Positive functional test 0.82 (0.46–1.48)
Age of vein graft 0.98 (0.94–1.03)
Pre-PCI RVD 1.32 (0.85–2.05)
Pre-PCI % stenosis 1.00 (0.98–1.02)
Pre-PCI thrombus 1.15 (0.65–2.05)
Baseline TIMI ﬂow grade 3 0.66 (0.23–1.90)
Log lesion length, mm 2.54 (1.59–4.04)
Thrombus grade 1.16 (0.65–2.05)
SVG degeneration (4-point scale) 1.56 (1.19–2.05)
Baseline TIMI ﬂow grade 1.35 (0.73–2.50)
Baseline % stenosis 1.00 (0.98–1.02)
Log plaque volume 1.97 (1.35–2.87)
CI confidence interval; CK-MB creatine kinase-myocardial band; CVA cardiovascular acciden
normal; other abbreviations as in Table 1.hough this represents a significant relative and absolute ueduction in adverse events for one of the highest-risk
ubsets of current PCI, the rate of adverse peri-procedural
vents remains high even with the use of embolic protec-
ion, and these peri-procedural events have been associated
ith significant morbidity and economic cost (13,14). Thus,
dentification of patients at the highest risk for peri-
rocedural complications can lead to appropriate risk-
tratification of patients before SVG PCI. Patients with
onger lesions in our study were at the highest risk of adverse
vents. Nonetheless, the observation of a 20% rate of
ACE with lesions above 20 mm (a lesion length not
raditionally considered extensive for conventional PCI)
uggests that there remains significant room for improve-
ent in the percutaneous treatment of SVG lesions, even if
reater penetrance of these devices is achieved. A recent
eport from the American College of Cardiology-National
ardiovascular Data Registry describes 25% use of em-
olic protection devices for SVG PCI overall (15). Whether
igher-risk patients such as those with longer lesions should
herefore lower the threshold for the use of an embolic
rotection device remains to be determined, but longer
esion length was associated with a higher incidence of the
Adjudicated MACE
p Value OR (95% CI) p Value
0.043 0.68 (0.37–1.24) 0.2
0.78 0.99 (0.97–1.02) 0.52
0.87 1.09 (0.85–1.40) 0.51
0.35 1.64 (0.91–2.97) 0.1
0.57 0.79 (0.43–1.46) 0.46
0.51 0.90 (0.42–1.97) 0.8
0.26 0.95 (0.56–1.58) 0.83
0.58 1.03 (0.49–2.17) 0.93
0.1 1.92 (0.80–4.57) 0.14
0.019 1.92 (1.07–3.45) 0.028
0.63 0.96 (0.53–1.74) 0.9
0.52 0.82 (0.48–1.41) 0.48
0.48 0.99 (0.94–1.03) 0.51
0.22 1.25 (0.84–1.87) 0.27
0.98 1.00 (0.98–1.01) 0.75
0.62 1.47 (0.86–2.51 0.16
0.44 0.80 (0.33–1.93) 0.62
0.001 2.81 (1.82–4.34) 0.001
0.62 1.47 (0.86–2.51) 0.16
0.002 1.53 (1.19–1.98) 0.001
0.34 1.12 (0.67–1.87) 0.66
0.98 1.00 (0.98–1.01) 0.75
0.001 2.01 (1.43–2.84) 0.001
odds ratio; RVD reference vessel diameter; TIA transient ischemic attack; ULN upper limit ofULN
t; ORse of an embolic protection device in that registry, sug-
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190esting that operators might be influenced by this lesion
haracteristic.
The observed association between lesion length and
utcomes in this study parallels that of other studies that
ave examined risk factors for adverse events in patients
ndergoing PCI with and without embolic protection (3,9).
onger lesions are thought to be representative of more
evere degenerative disease within an SVG (and therefore a
arger burden of debris with additionally greater potential to
mbolize). The observed correlation in this analysis between
esion length and angiographic plaque volume and the
emi-quantitative SVG degeneration score validates this
heory and is consistent with prior observations that esti-
ated plaque volume and diffuse disease within SVGs is
orrelated with peri-procedural adverse events as observed
lmost 15 years ago (16). It is notable that in the present
nalysis the simple metric of lesion length was the strongest
redictor of adverse events, particularly in comparison with
ore sophisticated angiographic measurements such as
laque volume.
It is unclear why the relationship between lesion length
nd outcomes persisted in the current study population that
as exclusively treated with embolic protection devices with
igh rates of technical success. Embolization might have
ccurred with wire or device crossing, and in this respect
alloon occlusion devices might have a theoretical advantage
ver filter-based devices, which typically have larger crossing
rofiles. Although this study was not adequately powered
o detect treatment effects between devices, we did not
bserve any interaction between lesion length and out-
omes among the 3 tested devices. Nonetheless, the
ccurrence of adverse events even in patients with the
4.3
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d
en
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CK-MB >3X ULN
Adjudicated MACE
Figure 1. Association Between Lesion Length and Rates of Adverse
Outcomes
The ﬁgure depicts the relationship between increasing lesion length and
the rates of adverse peri-procedural events (major adverse cardiac events
[MACE] and creatine kinase-myocardial band [CK-MB] elevation). ULN 
upper limit of normal.hortest lesions in this study—all of whom were treatedith embolic protection devices—stresses the high over-
ll risk of this patient population, even when treated with
djunctive embolic protection.
Interestingly, despite a mean graft age of 12 years and the
resence of several “high-risk” angiographic features such as
high prevalence of thrombus, we did not observe an
ssociation between adverse outcomes and graft age, throm-
us, or any other angiographic graft characteristics aside
rom lesion length. Several risk factors including thrombus
nd graft age have been described for SVG PCI without
istal embolic protection (3,6,7,10). It might be that the use
f embolic protection devices with high technical success
ates in this study has the ability to mitigate the risk
ssociated with some of the more traditional risk factors for
eri-procedural events. Further confirmatory studies are
ecessary to validate these observations.
tudy limitations. This analysis is a nonrandomized retro-
pective analysis, and as such it is possible that both
dentified and unidentified confounders might have influ-
nced the outcomes. The cohort of patients enrolled in
RIDE was a carefully selected clinical trial population that
et specific clinical and angiographic inclusion criteria.
hus the results of this trial might not be fully generalizable
o unselected patient populations. This study specifically
xcluded patients with significantly elevated CK-MB at
aseline, patients with severely depressed ejection fractions,
nd patients with the highest-risk acute coronary syn-
romes, such as ST-segment elevation myocardial infarc-
ion. One could anticipate that rates of adverse events would
e even higher among these patients, but whether the
ssociation we observed between lesion length and out-
omes would persist in these patient populations is un-
nown. In addition, because troponin levels were not
ystematically or prospectively collected, the definitions of
K-MB elevation and MACE do not include patients with
solated troponin elevations. Finally, whether these results
pply to embolic protection devices other than those studied
n PRIDE is unknown.
eprint requests and correspondence: Dr. Joseph P. Carrozza
r., Chief, Section of Interventional Cardiology, Beth Israel Dea-
oness Medical Center, 1 Deaconess Road, Baker 4, Boston,
assachusetts 02215. E-mail: jcarrozz@bidmc.harvard.edu.
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